



Press Release

## **CILCARE APPOINTS PATRICIA MACHADO AS EARLY DRUG DEVELOPMENT & PIPELINE DIRECTOR**

**Montpellier - France – September 30<sup>th</sup>, 2024** – Cilcare, a clinical-stage biotechnology company specializing in the development of therapeutics for inner ear disorders, is pleased to announce the appointment of Patricia Machado as its new Early Drug Development & Pipeline Director. With an impressive expertise in neuroscience and in the pharmaceutical industry, Dr Machado will be instrumental in defining and executing CILCARE’s strategy for advancing its drug pipeline to address the global need for innovative hearing disorder treatments.

Holding a PhD in neurosciences, as well as an Executive MBA in Management, Dr Machado brings over 13 years of experience in Research and Development at Pfizer and Servier, where she has held notable positions. Throughout her career, she has been deeply engaged in forging and managing strategic collaborations, significantly contributing to successful drug discovery and development projects. Her experience is further underscored by her in-depth knowledge of the regulatory landscape and her involvement in business development initiatives, which have led to several successful partnerships and publications.

In her new role at Cilcare, Dr Machado will strengthen R&D capability and provide scientific leadership and strategic guidance to develop a robust pipeline, opening new avenues for innovative hearing treatments. She will also spearhead the global licensing of assets and forge business partnerships to accelerate and strengthen the near and long-term pipeline. Her experience in due diligence, market analysis, and strategy will be invaluable in shaping CILCARE’s approach.

*“I am thrilled to join CILCARE at such a pivotal time,” said Patricia. “Hearing disorders remain a largely underexplored field with a vast, growing population in need. With more than 2.5 billion people projected to suffer from hearing loss by 2050, the scale of this public health issue is immense, far surpassing the prevalence of Alzheimer’s disease. CILCARE is uniquely positioned to make a significant impact on this insidious disease, which profoundly affects quality of life. I’m excited to bring my industrial mindset to a biotech committed to developing cutting-edge treatments that will shape the future of hearing healthcare.*



*"We are excited to have Patricia join our team" commented Celia Belline, CEO. "Her leadership and expertise will help drive our ambitious programs forward, ensuring that our pipeline delivers the groundbreaking solutions that millions of people worldwide are waiting for."*

Dr Machado's appointment underscores CILCARE's commitment to expanding its innovative pipeline and solidifying its leadership in the biotech ecosystem.

**About Cilcare:** Cilcare is a biotech established in 2014, dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. Cilcare's mission is to ensure hearing impairments are addressed earlier and with precision, as they are often associated with chronic diseases from their very early stages. As a catalyst in the development of pharmaceuticals, medical devices, gene therapies, and cell therapies for hearing loss and tinnitus, Cilcare is driving transformative breakthroughs.

Press contact:

## **CILCARE**

Marie PEYTAVY-IZARD

Director of Marketing & Communication

Tel : +33 (0)7 69 74 19 05

[marie.peytavy@cilcare.com](mailto:marie.peytavy@cilcare.com)

[www.cilcare.com](http://www.cilcare.com)